Last reviewed · How we verify

NCT07508046

Clinical Study on the Expression of PHGDH and Its Prognostic Value in Colorectal Cancer Patients Receiving Immunotherapy

Completed Last updated 2 April 2026
What this trial tests

trial testing No intervention in Colo-rectal Cancer in 100 participants. Completed in 1 January 2026.

Timeline
1 November 2025
Primary endpoint
1 January 2026
1 January 2026

Quick facts

Lead sponsorWest China Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date1 November 2025
Primary completion1 January 2026
Estimated completion1 January 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

West China Hospital

Who can join

Eligibility, any sex, with Colo-rectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the expression characteristics of PHGDH in tumor tissues based on the clinical data and pathological tissue samples of colorectal cancer patients who have previously received immunotherapy, and to analyze its correlation with patients' clinical features, immunotherapy efficacy, and survival prognosis, providing a basis for clarifying the clinical relevance of PHGDH.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Colo-rectal Cancer

Currently open trials in the same condition.

Other West China Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07508046.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing